A status update for a Phase 3 trial involving buserelin was recorded on June 25, 2026. The study, registered as NCT04513717 and titled "Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial," is designed to compare treatment intensity based on gene risk score in patients with high risk prostate cancer.
According to the update, the trial's current status is active, not recruiting. This designation means the study is ongoing but is no longer enrolling new participants. The trial remains in Phase 3.
No results have been posted as part of this update, and no efficacy or safety outcomes are described. The event data reflects only the trial's status and phase designation as of the listed date. Additional details on trial design, eligibility, and objectives are available through the official registry listing linked with this update.
Readers interested in buserelin can consult the compound overview for further background and context on its approved uses.